National trends in second-generation antipsychotic augmentation for nonpsychotic depression

Journal of Clinical Psychiatry

Volumn 75, Issue 5, 2014, Pages 490-497

  Gerhard, Tobias ^a,c   Akincigil, Ayse ^a,b   Correli, Christoph U ^d   Foglio, Neil J ^c   Crystal, Stephen ^a   Olfson, Mark ^e  

^a Rutgers University   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d Zucker Hillside Hospital Psychiatry Research North Shore Long Island Jewish Health System ^*  (United States)

^e Department of Psychiatry College of Physicians and Surg Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; NUMBERS NEEDED TO TREAT; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PSYCHOTHERAPY; PUBLIC HEALTH INSURANCE; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT RESPONSE; TREND STUDY;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; DRUG PRESCRIPTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; TIME FACTORS; YOUNG ADULT;

EID: 84901712944     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08675     Document Type: Article

References (59)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Arlington, VA: American Psychiatric Association; 2010
2. Nelson JC. The STAR*D study: a four-course meal that leaves us wanting more. Am ] Psychiatry. 2006;163(11):1864-1866. (Pubitemid 44807772)
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR.D report. Am J Psychiatry. 2006;163(11):1905-1917. (Pubitemid 44807782
4. Papakostas Gì, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry. 2008;63(7):699-704. (Pubitemid 351329277
5. Thase ME. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry. 2011;56(6):317-323
6. Nelson JC, Papakostas GL Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
7. Dirmaier J, Steinmann M, Krattenmacher T, et al. Non-pharmacological treatment of depressive disorders: a review of evidence-based treatment options. Rev Recent Clin Trials. 2012;7(2):141-149.
8. Khullar A, Chokka P, Fullerton D, et al. A double-blind, randomized, placebo-controlled study of quetiapine as augmentation therapy to SSRI/ SNRI agents in the treatment of non-psychotic unipolar depression with residual symptoms. In: American Psychiatric Association 2006Annual Meeting: New Research Abstracts. Washington, DC: American Psychiatric Association; 2006.
9. Mattingly G, Ilivicky H, Canale J, et al. Quetiapine combination for treatment-resistant depression. In: American Psychiatric Association 2006 Annual Meeting: New Research Abstracts. Washington, DC: American Psychiatric Association; 2006.
10. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540-549.
11. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
12. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. (Pubitemid 47015482
13. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006; 23(6):364-372. (Pubitemid 44619788
14. E1-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. IntJNeuropsychopharmacol. 2010;13(7):917-932.
15. Keitner Gì, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009;43(3):205-214.
16. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593-602. (Pubitemid 351664478
17. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychoparmacol 2008;28(2):156-165. (Pubitemid 351417120
18. Mclntyre A, Gendron A, Mclntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007; 24(7):487-494. (Pubitemid 350086262
19. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(8):1228-1236.
20. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am I Psychiatry. 2001;158(1):131-134. (Pubitemid 32047260
21. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10):1289-1297. (Pubitemid 41546509
22. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007; 68(2):224-236. (Pubitemid 46362643
23. Philip NS, Carpenter LL, Tyrka AR, et al. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010;ll(5):709-722.
24. Correli CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425. (Pubitemid 38326094
25. Rumme1-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1): 167-177.
26. Correli CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107.
27. De Hert M, Correli CU, Bobes J, et al. Physical illness in patients with severe mental disorders, 1: prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77.
28. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126.
29. Nielsen J, Skadhede S, Correli CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997-2004.
30. Correli CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
31. De Hert M, Vancampfort D, Correli CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199(2):99-105.
32. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders, 2: barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138-151.
33. Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125-147.
34. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337(2):al227.
35. Partente A, Fourrier-Réglat A, Ducruet T, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Mem Med. 2012;172(8):648-653, discussion 654-655.
36. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. NEngl J Med. 2009;360(3):225-235.
37. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943. (Pubitemid 41464695
38. Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the US Department of Veterans Affairs. J Clin Psychiatry. 2009;70(6):906-912.
39. Fullerton CA, Busch AB, Normand SL, et al. Ten-year trends in quality of care and spending for depression: 1996 through 2005. Arch Gen Psychiatry. 2011;68(12):1218-1226.
40. Ambulatory health care data. Questionnaires, datasets, and related documentation. Centers for Disease Control and Prevention Web site, http://www.cdc.gov/nchs/ahcd/ahcd-questionnaires.htm. Updated June 28,2013. Accessed April 3,2013.
41. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010; 67(1):26-36.
42. Hing E, Gousen S, Shimizu I, et al. Guide to using masked design variables to estimate standard errors in public use files of the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Inquiry. 2003;40(4):401-415. (Pubitemid 38365288
43. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs. 2009;23(7):583-602.
44. Glassman AH. Depression and cardiovascular comorbidity. Dialogues Clin Neurosci. 2007;9(1):9-17. (Pubitemid 46607127
45. Iosifescu DV, Clementi-Craven N, Fraguas R, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005;67(5):703-706.
46. Kan C, Silva N, Golden SH, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 2013;36(2):480-489.
47. Mclntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep. 2009;9(1):51-59.
48. Mclntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann Clin Psychiatry. 2007; 19(4):257-264. (Pubitemid 350208796
49. Pan A, Lucas M, Sun Q, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170(21): 1884-1891.
50. Stapelberg NJ, Neumann DL, Shum DH, et al. A topographical map of the causal network of mechanisms underlying the relationship between major depressive disorder and coronary heart disease. Aust NZ J Psychiatry. 2011; 45(5):351-369.
51. FDA Public Health Advisory. Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetylnformationforPatientsandProviders/ DrogSafetylnformationforHeamcareProfessionds/PublicHedthAdvisories/ucm053171. Updated August 16,2013. Accessed January 18,2013.
52. Hodgkin D, Horgan CM, Garnick DW, et al. Management of access to branded psychotropic medications in private health plans. Clin Ther. 2007; 29(2):371-380. (Pubitemid 46654225
53. Huskamp HA. Pharmaceutical cost management and access to psychotropic drugs: the US context. Int J Law Psychiatry. 2005;28(5):484-495. (Pubitemid 41338401
54. Cuijpers P, Dekker J, Hollon SD, et al. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009;70(9):1219-1229.
55. Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61(7):714-719. (Pubitemid 38890806
56. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet. 2013;381(9864):375-384.
57. Mojtabai R Olfson M. National trends in psychotherapy by office-based psychiatrists. Arch Gen Psychiatry. 2008;65(8):962-970.
58. Cascade EF, Kalali AH, Lieberman J, et al. Use of antipsychotics pre-and post-dissemination of CATIE data. Psychiatry (Edgmont). 2007;4(5):21-23.
59. Shear MK, Greeno C, Kang J, et al. Diagnosis of nonpsychotic patients in community clinics. Am J Psychiatry. 2000;157(4):581-587. (Pubitemid 30191197)